Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Feb;73(4):539–542. doi: 10.1038/bjc.1996.93

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.

H R Bonnefoi 1, I E Smith 1, M Dowsett 1, P F Trunet 1, S J Houston 1, R J da Luz 1, R D Rubens 1, R C Coombes 1, T J Powles 1
PMCID: PMC2074462  PMID: 8595171

Abstract

The endocrine and therapeutic effects of the aromatase inhibitor fadrozole hydrochloride have been assessed in 80 post-menopausal patients with recurrent breast cancer after tamoxifen failure. Treatment allocation was randomly 0.5, 1.0 or 2.0 mg orally b.d. Eight patients were not assessable for response. All patients were evaluated for toxicity (intent-to-treat analysis). In general, the patients' characteristics were well balanced between the three randomised groups. The endocrine data from this study previously reported suggest a dose-related suppression of oestrone, but not oestradiol or oestrone sulphate. The objective response rate was 17% (95% CI 8.9-27.3%) with no complete responders. Fifteen patients (21%) had stable disease (NC) and 45 patients (63%) had progressive disease (PD). The median duration of objective response was 36 weeks. The median time to treatment failure was 12.7 weeks. The log-rank test showed no statistical difference between the dosage groups. The main adverse events reported were mild to moderate severity: nausea in 11 patients (15%), hot flashes in four (5%) and somnolence in three (4%). No serious adverse events were reported. In conclusion, fadrozole is a clinically active aromatase inhibitor with a low incidence of side-effects and phase III clinical trials in post-menopausal women are currently under way.

Full text

PDF
539

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beretta K. R., Hoeffken K., Kvinnsland S., Trunet P., Chaudri H. A., Bhatnagar A. S., Goldhirsch A., Cavalli F. CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study. Ann Oncol. 1990 Nov;1(6):421–426. doi: 10.1093/oxfordjournals.annonc.a057795. [DOI] [PubMed] [Google Scholar]
  2. Dowsett M. Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1037–1041. doi: 10.1016/0960-0760(90)90462-t. [DOI] [PubMed] [Google Scholar]
  3. Dowsett M., Smithers D., Moore J., Trunet P. F., Coombes R. C., Powles T. J., Rubens R., Smith I. E. Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. Eur J Cancer. 1994;30A(10):1453–1458. doi: 10.1016/0959-8049(94)00281-9. [DOI] [PubMed] [Google Scholar]
  4. Dowsett M., Stein R. C., Mehta A., Coombes R. C. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol (Oxf) 1990 May;32(5):623–634. doi: 10.1111/j.1365-2265.1990.tb00906.x. [DOI] [PubMed] [Google Scholar]
  5. Goss P. E., Gwyn K. M. Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol. 1994 Nov;12(11):2460–2470. doi: 10.1200/JCO.1994.12.11.2460. [DOI] [PubMed] [Google Scholar]
  6. Hayward J. L., Carbone P. P., Heusen J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977 Mar;35(3):292–298. doi: 10.1038/bjc.1977.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lipton A., Harvey H. A., Demers L. M., Hanagan J. R., Mulagha M. T., Kochak G. M., Fitzsimmons S., Sanders S. I., Santen R. J. A phase I trial of CGS 16949A. A new aromatase inhibitor. Cancer. 1990 Mar 15;65(6):1279–1285. doi: 10.1002/1097-0142(19900315)65:6<1279::aid-cncr2820650604>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  8. Lipton A., Santner S. J., Santen R. J., Harvey H. A., Feil P. D., White-Hershey D., Bartholomew M. J., Antle C. E. Aromatase activity in primary and metastatic human breast cancer. Cancer. 1987 Feb 15;59(4):779–782. doi: 10.1002/1097-0142(19870215)59:4<779::aid-cncr2820590419>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  9. Longcope C., Pratt J. H., Schneider S. H., Fineberg S. E. Aromatization of androgens by muscle and adipose tissue in vivo. J Clin Endocrinol Metab. 1978 Jan;46(1):146–152. doi: 10.1210/jcem-46-1-146. [DOI] [PubMed] [Google Scholar]
  10. MacNeill F. A., Jones A. L., Jacobs S., Lønning P. E., Powles T. J., Dowsett M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer. 1992 Oct;66(4):692–697. doi: 10.1038/bjc.1992.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Miller W. R. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev. 1989 Jun;16(2):83–93. doi: 10.1016/0305-7372(89)90012-1. [DOI] [PubMed] [Google Scholar]
  12. Murray R., Pitt P. Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. Eur J Cancer Clin Oncol. 1985 Jan;21(1):19–22. doi: 10.1016/0277-5379(85)90195-6. [DOI] [PubMed] [Google Scholar]
  13. Powles T. J. The role of aromatase inhibitors in breast cancer. Semin Oncol. 1983 Dec;10(4 Suppl 4):20–24. [PubMed] [Google Scholar]
  14. Raats J. I., Falkson G., Falkson H. C. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J Clin Oncol. 1992 Jan;10(1):111–116. doi: 10.1200/JCO.1992.10.1.111. [DOI] [PubMed] [Google Scholar]
  15. Santen R. J., Demers L. M., Adlercreutz H., Harvey H., Santner S., Sanders S., Lipton A. Inhibition of aromatase with CGS 16949A in postmenopausal women. J Clin Endocrinol Metab. 1989 Jan;68(1):99–106. doi: 10.1210/jcem-68-1-99. [DOI] [PubMed] [Google Scholar]
  16. Santen R. J., Lipton A., Kendall J. Successful medical adrenalectomy with amino-glutethimide. Role of altered drug metabolism. JAMA. 1974 Dec 23;230(12):1661–1665. [PubMed] [Google Scholar]
  17. Santen R. J., Santner S., Davis B., Veldhuis J., Samojlik E., Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab. 1978 Dec;47(6):1257–1265. doi: 10.1210/jcem-47-6-1257. [DOI] [PubMed] [Google Scholar]
  18. Steele R. E., Mellor L. B., Sawyer W. K., Wasvary J. M., Browne L. J. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A. Steroids. 1987 Jul-Sep;50(1-3):147–161. doi: 10.1016/0039-128x(83)90068-5. [DOI] [PubMed] [Google Scholar]
  19. Stein R. C., Dowsett M., Davenport J., Hedley A., Ford H. T., Gazet J. C., Coombes R. C. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Cancer Res. 1990 Mar 1;50(5):1381–1384. [PubMed] [Google Scholar]
  20. Stuart-Harris R. C., Smith I. E. Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev. 1984 Sep;11(3):189–204. doi: 10.1016/0305-7372(84)90008-2. [DOI] [PubMed] [Google Scholar]
  21. Stuart-Harris R., Dowsett M., Bozek T., McKinna J. A., Gazet J. C., Jeffcoate S. L., Kurkure A., Carr L., Smith I. E. Low-dose aminoglutethimide in treatment of advanced breast cancer. Lancet. 1984 Sep 15;2(8403):604–607. doi: 10.1016/s0140-6736(84)90596-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES